Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281777449> ?p ?o ?g. }
- W4281777449 endingPage "8014" @default.
- W4281777449 startingPage "8014" @default.
- W4281777449 abstract "8014 Background: Elranatamab (PF-06863135) is a bispecific molecule that activates and redirects the T-cell mediated immune response against multiple myeloma (MM), a plasma cell dyscrasia characterized by expression of B-cell maturation antigen (BCMA). MagnetisMM-1 (NCT03269136), the ongoing Phase 1 first-in-human study for elranatamab, was designed to characterize safety, pharmacokinetics (PK), pharmacodynamics, and efficacy for patients (pts) with relapsed or refractory MM. Methods: Elranatamab was given subcutaneously (SC) at doses from 80 to 1000µg/kg either weekly or every 2 weeks (Q2W). Treatment-emergent adverse events (TEAEs) were graded by Common Terminology Criteria for Adverse Events (v4.03) and cytokine release syndrome (CRS) by American Society for Transplantation and Cellular Therapy criteria. PK, cytokine and soluble BCMA profiling, and lymphocyte subset analyses were performed. Response was assessed by International Myeloma Working Group (IMWG) criteria. Minimal residual disease (MRD) was assessed by next generation sequencing at a sensitivity of 1×10 -5 in accordance with IMWG criteria. Results: A total of 55 pts received single-agent elranatamab SC at a dose ≥215μg/kg as of 1-Nov-2021. Median age was 64 (range 42-80) years, and 27% of pts were Black/African American or Asian. Median number of prior regimens was 6 (range 2-15), 91% were triple-class refractory, 56% had prior stem cell transplantation, 27% had high cytogenetic risk, and 22% received prior BCMA-targeted therapy. The most common TEAEs regardless of causality included CRS, neutropenia, anemia, injection site reaction, and lymphopenia. With pre-medication and a single priming dose (600µg/kg or 44mg), the overall incidence of CRS at the recommended dose (1000µg/kg or 76mg) was 67% and limited to Grade 1 (33%) or Grade 2 (33%), with no events Grade 3 or higher. Exposure was dose dependent and Q2W dosing achieved exposure associated with anti-myeloma efficacy. Cytokine increases occurred with the first dose and were reduced by pre-medication. Soluble BCMA decreased with disease response, elranatamab therapy was associated with increased peripheral T cell proliferation, and median time to response was 36 days (range 7-73). With a median follow-up of 8.1 months (range 0.3-21) and including only IMWG confirmed responses, 31% of pts achieved complete response or better and the overall response rate was 64% (95% CI 50-75%). For responders (n = 35), median duration of response was not yet reached, but the probability of being event-free at 6 months was 91% (95% CI 73-97%). Single-agent elranatamab induces durable clinical and molecular responses, and updated data including MRD assessment will be presented. Conclusions: Elranatamab shows a manageable safety profile and achieves durable clinical and molecular responses for pts with relapsed or refractory MM. Clinical trial information: NCT03269136." @default.
- W4281777449 created "2022-06-13" @default.
- W4281777449 creator A5004066032 @default.
- W4281777449 creator A5032617342 @default.
- W4281777449 creator A5033588007 @default.
- W4281777449 creator A5033810238 @default.
- W4281777449 creator A5036363023 @default.
- W4281777449 creator A5036543091 @default.
- W4281777449 creator A5041503485 @default.
- W4281777449 creator A5043163773 @default.
- W4281777449 creator A5052048627 @default.
- W4281777449 creator A5055922112 @default.
- W4281777449 creator A5057911528 @default.
- W4281777449 creator A5063578659 @default.
- W4281777449 creator A5063797971 @default.
- W4281777449 creator A5064552806 @default.
- W4281777449 creator A5065238694 @default.
- W4281777449 creator A5074922531 @default.
- W4281777449 creator A5082712392 @default.
- W4281777449 creator A5083329029 @default.
- W4281777449 creator A5087389702 @default.
- W4281777449 creator A5088804902 @default.
- W4281777449 date "2022-06-01" @default.
- W4281777449 modified "2023-10-16" @default.
- W4281777449 title "Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1." @default.
- W4281777449 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.8014" @default.
- W4281777449 hasPublicationYear "2022" @default.
- W4281777449 type Work @default.
- W4281777449 citedByCount "6" @default.
- W4281777449 countsByYear W42817774492022 @default.
- W4281777449 countsByYear W42817774492023 @default.
- W4281777449 crossrefType "journal-article" @default.
- W4281777449 hasAuthorship W4281777449A5004066032 @default.
- W4281777449 hasAuthorship W4281777449A5032617342 @default.
- W4281777449 hasAuthorship W4281777449A5033588007 @default.
- W4281777449 hasAuthorship W4281777449A5033810238 @default.
- W4281777449 hasAuthorship W4281777449A5036363023 @default.
- W4281777449 hasAuthorship W4281777449A5036543091 @default.
- W4281777449 hasAuthorship W4281777449A5041503485 @default.
- W4281777449 hasAuthorship W4281777449A5043163773 @default.
- W4281777449 hasAuthorship W4281777449A5052048627 @default.
- W4281777449 hasAuthorship W4281777449A5055922112 @default.
- W4281777449 hasAuthorship W4281777449A5057911528 @default.
- W4281777449 hasAuthorship W4281777449A5063578659 @default.
- W4281777449 hasAuthorship W4281777449A5063797971 @default.
- W4281777449 hasAuthorship W4281777449A5064552806 @default.
- W4281777449 hasAuthorship W4281777449A5065238694 @default.
- W4281777449 hasAuthorship W4281777449A5074922531 @default.
- W4281777449 hasAuthorship W4281777449A5082712392 @default.
- W4281777449 hasAuthorship W4281777449A5083329029 @default.
- W4281777449 hasAuthorship W4281777449A5087389702 @default.
- W4281777449 hasAuthorship W4281777449A5088804902 @default.
- W4281777449 hasConcept C121608353 @default.
- W4281777449 hasConcept C126322002 @default.
- W4281777449 hasConcept C143998085 @default.
- W4281777449 hasConcept C197934379 @default.
- W4281777449 hasConcept C203014093 @default.
- W4281777449 hasConcept C2776364478 @default.
- W4281777449 hasConcept C2776694085 @default.
- W4281777449 hasConcept C2777063308 @default.
- W4281777449 hasConcept C2777701055 @default.
- W4281777449 hasConcept C2777793932 @default.
- W4281777449 hasConcept C2779050716 @default.
- W4281777449 hasConcept C2779823535 @default.
- W4281777449 hasConcept C2780007613 @default.
- W4281777449 hasConcept C2780850621 @default.
- W4281777449 hasConcept C2911091166 @default.
- W4281777449 hasConcept C3875195 @default.
- W4281777449 hasConcept C71924100 @default.
- W4281777449 hasConcept C90924648 @default.
- W4281777449 hasConceptScore W4281777449C121608353 @default.
- W4281777449 hasConceptScore W4281777449C126322002 @default.
- W4281777449 hasConceptScore W4281777449C143998085 @default.
- W4281777449 hasConceptScore W4281777449C197934379 @default.
- W4281777449 hasConceptScore W4281777449C203014093 @default.
- W4281777449 hasConceptScore W4281777449C2776364478 @default.
- W4281777449 hasConceptScore W4281777449C2776694085 @default.
- W4281777449 hasConceptScore W4281777449C2777063308 @default.
- W4281777449 hasConceptScore W4281777449C2777701055 @default.
- W4281777449 hasConceptScore W4281777449C2777793932 @default.
- W4281777449 hasConceptScore W4281777449C2779050716 @default.
- W4281777449 hasConceptScore W4281777449C2779823535 @default.
- W4281777449 hasConceptScore W4281777449C2780007613 @default.
- W4281777449 hasConceptScore W4281777449C2780850621 @default.
- W4281777449 hasConceptScore W4281777449C2911091166 @default.
- W4281777449 hasConceptScore W4281777449C3875195 @default.
- W4281777449 hasConceptScore W4281777449C71924100 @default.
- W4281777449 hasConceptScore W4281777449C90924648 @default.
- W4281777449 hasIssue "16_suppl" @default.
- W4281777449 hasLocation W42817774491 @default.
- W4281777449 hasOpenAccess W4281777449 @default.
- W4281777449 hasPrimaryLocation W42817774491 @default.
- W4281777449 hasRelatedWork W2318150798 @default.
- W4281777449 hasRelatedWork W2364188423 @default.
- W4281777449 hasRelatedWork W2379764382 @default.
- W4281777449 hasRelatedWork W2582431155 @default.
- W4281777449 hasRelatedWork W2981308154 @default.
- W4281777449 hasRelatedWork W3004485101 @default.